Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors.

Tytuł :
Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors.
Autorzy :
Sampedro-Núñez M; Services of Endocrinology, Immunology and Molecular Biology Unit, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Instituto Princesa, 28006, Madrid, Spain.
Serrano-Somavilla A; Services of Endocrinology, Immunology and Molecular Biology Unit, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Instituto Princesa, 28006, Madrid, Spain.
Adrados M; Service of Pathology, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, 28006, Madrid, Spain.
Cameselle-Teijeiro JM; Service of Pathology, Hospital Clinico Universitario, Universidad de Santiago de Compostela, Santiago de Compostela, 15706, Spain.
Blanco-Carrera C; Service of Endocrinology, Hospital Universitario de Alcalá de Henares, Universidad de Alcalá de Henares, 28805, Madrid, Spain.
Cabezas-Agricola JM; Service of Endocrinology, Hospital Clinico Universitario, Universidad de Santiago de Compostela, Santiago de Compostela, 15706, Spain.
Martínez-Hernández R; Services of Endocrinology, Immunology and Molecular Biology Unit, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Instituto Princesa, 28006, Madrid, Spain.
Martín-Pérez E; Service of Surgery, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Instituto Princesa, 28006, Madrid, Spain.
Muñoz de Nova JL; Service of Surgery, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Instituto Princesa, 28006, Madrid, Spain.
Díaz JÁ; Service of Endocrinology, Hospital Clinico San Carlos, Universidad Complutense de Madrid, Madrid, 28040, Spain.
García-Centeno R; Service of Endocrinology, Hospital Universitario Gregorio Marañón, Madrid, 28007, Spain.
Caneiro-Gómez J; Service of Pathology, Hospital Clinico Universitario, Universidad de Santiago de Compostela, Santiago de Compostela, 15706, Spain.
Abdulkader I; Service of Pathology, Hospital Clinico Universitario, Universidad de Santiago de Compostela, Santiago de Compostela, 15706, Spain.
González-Amaro R; Department of Immunology, School of Medicine, Universidad Autónoma de San Luis Potosí, 78210 S.L.P., San Luis, Mexico.; Research Center of Health Sciences and Biomedicine, Universidad Autónoma de San Luis Potosí, 78210 S.L.P., San Luis, Mexico.
Marazuela M; Services of Endocrinology, Immunology and Molecular Biology Unit, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Instituto Princesa, 28006, Madrid, Spain. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2018 Dec 13; Vol. 8 (1), pp. 17812. Date of Electronic Publication: 2018 Dec 13.
Typ publikacji :
Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Język :
English
Imprint Name(s) :
Original Publication: London : Nature Publishing Group, copyright 2011-
MeSH Terms :
Gene Expression Regulation, Neoplastic*
Intestinal Neoplasms*/diagnosis
Intestinal Neoplasms*/metabolism
Intestinal Neoplasms*/pathology
Neuroendocrine Tumors*/diagnosis
Neuroendocrine Tumors*/metabolism
Neuroendocrine Tumors*/pathology
Pancreatic Neoplasms*/diagnosis
Pancreatic Neoplasms*/metabolism
Pancreatic Neoplasms*/pathology
Stomach Neoplasms*/diagnosis
Stomach Neoplasms*/metabolism
Stomach Neoplasms*/pathology
B7-H1 Antigen/*biosynthesis
Neoplasm Proteins/*biosynthesis
Programmed Cell Death 1 Receptor/*biosynthesis
Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Prognosis ; Retrospective Studies
References :
Cancer Cell. 2015 Apr 13;27(4):450-61. (PMID: 25858804)
J Immunol. 2007 Mar 1;178(5):2763-9. (PMID: 17312119)
J Cancer. 2016 Feb 05;7(5):484-9. (PMID: 26958083)
Oncotarget. 2018 Feb 12;9(19):14922-14938. (PMID: 29599916)
J Clin Oncol. 2014 Apr 1;32(10):1020-30. (PMID: 24590637)
Cell Death Dis. 2017 Aug 24;8(8):e3004. (PMID: 28837143)
J Clin Oncol. 2015 Jun 20;33(18):2013-20. (PMID: 25800770)
Histopathology. 2018 Jan;72(1):153-167. (PMID: 29239038)
Immunol Rev. 2010 Jul;236:219-42. (PMID: 20636820)
Oncotarget. 2017 May 30;8(22):36885-36897. (PMID: 28415570)
Nature. 2014 Nov 27;515(7528):558-62. (PMID: 25428503)
Nat Immunol. 2001 Mar;2(3):261-8. (PMID: 11224527)
J Exp Med. 2009 Dec 21;206(13):3015-29. (PMID: 20008522)
Nat Immunol. 2013 Oct;14(10):1014-22. (PMID: 24048123)
Z Rheumatol. 2015 Apr;74(3):230-9. (PMID: 24942602)
J Clin Oncol. 2010 Jul 1;28(19):3167-75. (PMID: 20516446)
J Immunol. 2014 Oct 15;193(8):3835-41. (PMID: 25281753)
J Clin Oncol. 2008 Jun 20;26(18):3063-72. (PMID: 18565894)
Eur J Immunol. 2003 Oct;33(10):2706-16. (PMID: 14515254)
Annu Rev Immunol. 2008;26:677-704. (PMID: 18173375)
J Immunol. 2002 Nov 15;169(10):5538-45. (PMID: 12421930)
Clin Cancer Res. 2014 Oct 1;20(19):5064-74. (PMID: 24714771)
J Immunother Cancer. 2018 Jan 23;6(1):8. (PMID: 29357948)
Cancer Res. 2009 Oct 15;69(20):8067-75. (PMID: 19826049)
Am J Clin Oncol. 2016 Feb;39(1):98-106. (PMID: 26558876)
Eur J Cancer. 2015 Feb;51(3):421-6. (PMID: 25582496)
Nat Rev Immunol. 2008 Jun;8(6):467-77. (PMID: 18500231)
Neuroendocrinology. 2017 Apr 8;105(3):201-211. (PMID: 28391265)
Onco Targets Ther. 2016 Oct 06;9:6075-6082. (PMID: 27785054)
Cancer J. 2018 Jan/Feb;24(1):47-53. (PMID: 29360728)
Contemp Oncol (Pozn). 2017;21(2):115-122. (PMID: 28947880)
J Exp Med. 2009 Jun 8;206(6):1327-37. (PMID: 19451266)
J Leukoc Biol. 2013 Jul;94(1):25-39. (PMID: 23625198)
Mol Cell Biol. 2005 Nov;25(21):9543-53. (PMID: 16227604)
Oncotarget. 2016 Aug 30;7(35):56233-56240. (PMID: 27191652)
Nat Med. 2002 Aug;8(8):793-800. (PMID: 12091876)
Nat Med. 1999 Dec;5(12):1365-9. (PMID: 10581077)
Nat Commun. 2015 Jan 22;6:5997. (PMID: 25609381)
Lung Cancer. 2017 Jun;108:115-120. (PMID: 28625622)
Substance Nomenclature :
0 (B7-H1 Antigen)
0 (CD274 protein, human)
0 (Neoplasm Proteins)
0 (PDCD1 protein, human)
0 (Programmed Cell Death 1 Receptor)
SCR Disease Name :
Gastro-enteropancreatic neuroendocrine tumor
Entry Date(s) :
Date Created: 20181215 Date Completed: 20191021 Latest Revision: 20200309
Update Code :
20210210
PubMed Central ID :
PMC6292913
DOI :
10.1038/s41598-018-36129-1
PMID :
30546030
Czasopismo naukowe
The immune checkpoint based therapy targeting the programmed death-1 (PD-1) receptor and its PD-L1 ligand has recently been approved for the therapy of different malignant conditions, but not yet for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). In this context, we evaluated the expression of PD-1 and PD-L1 in GEP-NETs and its potential correlations with clinical outcomes. Expression of PD-1/PD-L1 was analyzed by immunohistochemistry in 116 GEP-NETs and 48 samples of peritumoral tissue. In addition, the expression of these molecules was assessed by flow cytometry in peripheral blood mononuclear cells (PBMC) from patients with GEP-NETs (n = 32) and healthy controls (n = 32) and in intratumoral mononuclear cells (TMCs) (n = 3). Expression of PD-L1 and PD-1 was detected by immunohistochemistry in 6% and 1% of tumor tissue samples, respectively, and in 8% of peritumoral tissue samples, for both markers. We also observed that PD-1 expression by TMCs was associated with metastatic disease at diagnosis, and the levels of circulating PD-1+ PBMCs were associated with progressive disease upon follow-ups. In addition, circulating PD-1+ PBMCs were significantly correlated with PD-L1 expression by tumor cells. Our data suggest that PD-1/PD-L1 is expressed in 1 to 8% of GEP-NETs, and that this feature is significantly associated with disease evolution (p < 0.01).
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies